These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2924375)

  • 1. Pharmacokinetics of tauromustine in cancer patients. Phase I studies.
    Gunnarsson PO; Vibe-Petersen J; Macpherson JS; Warrington PS; Polacek J; Ellman M; Hansen HH; Smyth JF
    Cancer Chemother Pharmacol; 1989; 23(3):176-80. PubMed ID: 2924375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of TCNU, a novel nitrosourea.
    Smyth JF; Macpherson JS; Warrington PS; Kerr ME; Whelan JM; Cornbleet MA; Leonard RC
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1845-9. PubMed ID: 3436348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
    Bibby MC; Loadman PM; al-Ghabban AF; Double JA
    Br J Cancer; 1992 Mar; 65(3):347-50. PubMed ID: 1558786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU).
    Hartley-Asp B; Christensson PI; Gunnarsson K; Gunnarsson PO; Jensen G; Polacek J; Stamvik A
    Invest New Drugs; 1988 Apr; 6(1):19-30. PubMed ID: 3410663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome aberrations and pharmacokinetics in patients receiving tauromustine as either a single or a repeated dose.
    Hartley-Asp B; Hansson K; Vibe-Petersen J; Hansen HH; Polacek J; Ellman M; Gunnarsson PO
    Cancer Chemother Pharmacol; 1996; 38(4):309-16. PubMed ID: 8674152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications.
    Whittle IR; MacPherson JS; Miller JD; Smyth JF
    J Neurosurg; 1990 May; 72(5):721-5. PubMed ID: 2157825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice.
    Hill SR; Bibby MC
    Cancer Chemother Pharmacol; 1994; 34(1):57-62. PubMed ID: 8174203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental cerebral and plasma pharmacokinetic studies of TCNU: implications for brain tumour chemotherapy.
    Whittle IR; Macpherson JS; Smyth J; Miller JD
    Br J Neurosurg; 1987; 1(3):365-8. PubMed ID: 3268132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of tauromustine in disseminated malignant melanoma.
    Nolte H; Gjedde SB; Lindegaard-Madsen E; Bergh J; Blomquist E; Mouridsen HT
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):655-7. PubMed ID: 2714342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotoxicity of tauromustine, a new water soluble taurine-based nitrosourea. I. Mutagenic and clastogenic activity of tauromustine in vitro.
    Hartley-Asp B
    Mutagenesis; 1992 Nov; 7(6):427-31. PubMed ID: 1474918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of tauromustine, a nitrosourea-based antitumour agent, in plasma by high-performance liquid chromatography.
    Polacek J; Gunnarsson PO; Brandin S
    J Chromatogr; 1988 Mar; 425(2):424-8. PubMed ID: 3372655
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy with tauromustine in advanced non-small cell lung cancer. A trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society.
    Gatzemeier U; Drings P; Edler L; Fiebig HH; Hinke A; Rieche K; Tessen HW
    Onkologie; 1990 Jun; 13(3):186-8. PubMed ID: 2168534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU).
    Vibe-Petersen J; Bork E; Møller H; Hansen HH
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1837-43. PubMed ID: 3436347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a new nitrosourea (TCNU) in human lung cancer xenografts.
    Fergusson RJ; Anderson LE; Macpherson JS; Robins P; Smyth JF
    Br J Cancer; 1988 Apr; 57(4):339-42. PubMed ID: 3390369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of tauromustine and its demethylated metabolites in plasma and urine.
    Polacek J; Gustafsson B; Brandin S; Ottersgård-Brorsson A
    J Chromatogr; 1990 Mar; 526(1):151-7. PubMed ID: 2341526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. EORTC Early Clinical Trials Group.
    Gundersen S; Dombernowsky P; Cavalli F; Bruntsch U; Renard J; Van Glabbeke M; Pinedo H
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1095-7. PubMed ID: 2759163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations.
    Double JA; Bibby MC; Loadman PM; Bloomer JC
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1355-60. PubMed ID: 3181256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tauromustine is more effective than conventional chemotherapy in the treatment of colonic tumors.
    Singh G; Graffner HO; Milsom JW; Chaudry IH
    Dis Colon Rectum; 1993 Apr; 36(4):394-9. PubMed ID: 8458268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement and characterization of the denitrosation of tauromustine and related nitrosoureas by glutathione transferases in liver cytosol from various species.
    Tuvesson H; Gunnarsson PO; Seidegård J
    Carcinogenesis; 1993 Jun; 14(6):1143-7. PubMed ID: 8508500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of different dose levels of degradable starch microspheres (Spherex) on the distribution of a cytotoxic drug after regional administration to tumour-bearing rats.
    Teder H; Johansson CJ; d'Argy R; Lundin N; Gunnarsson PO
    Eur J Cancer; 1995 Sep; 31A(10):1701-5. PubMed ID: 7488428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.